South San Francisco, CA, and Berkeley, CA Genentech, Inc. (NYSE: DNA) and XOMA Ltd. (Nasdaq: XOMA) announced today that RAPTIVA (efalizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic moderate-to-severe plaque psoriasis in adults age 18 or older who are candidates for systemic therapy or phototherapy. RAPTIVA is the first biologic therapy that is designed to provide continuous control of chronic moderate-to-severe plaque psoriasis and can be self-administered by patients as a single, once-weekly, subcutaneous injection.
"Today's FDA approval of RAPTIVA underscores our commitment to delivering innovative therapies to patients with unmet medical needs," said Arthur D. Levinson, Ph.D., Genentech's chairman and chief executive officer. "Through our collaboration with XOMA, the clinical trial investigators and most importantly, the over 2,700 patients who participated in our clinical trials, we are proud to offer a new therapeutic option to help patients manage this chronic disease."
"RAPTIVA represents XOMA's first product approval and is the culmination of a highly successful collaboration with Genentech," said John L. Castello, XOMA's chairman, president and chief executive officer. "The companies have worked together on a robust clinical program that has demonstrated the safety and efficacy of RAPTIVA. We view RAPTIVA now being available to
patients as a worthy testament to the confidence of our shareholders and the hard work and support of both companies'
"I've been treating psoriasis for over 15 years and have always been frustrated by the limited options available to treat patients with this chronic disease. Safety limitations of traditional therapies have made it difficult to offer patients continuous relief," said Craig Leonardi, M.D., clinical associate professor of dermatology of Saint Louis University, St. Louis, Mo. and a RAPTIVA clinical investigator. "RAPTIVA Page: 1 2 3 4 5 6 Related biology news :1
Contact: Emmy Tsui
. FDA approves VYTORIN, first and only to powerfully reduce LDL cholesterol through dual inhibition2
. European Commission approves Herceptin + Taxotere as 1st-line therapy in HER2-positive breast cancer3
. FDA approves Abbotts Biaxin XL (clarithromycin extended-release tablet)for community-acquired pneumonia4
. FDA approves new treatment, Campath , humanized monoclonal antibody, for patients with B-cell chronic lymphocytic leukemia5
. DFG approves 14 new research training units6
. National Science Board approves five new NSF Science and Technology Centers7
. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting8
. Results from open-label Raptiva study suggest continued benefit with long-term treatment9
. Genes appear to play a role in development of chronic obstructive pulmonary disease10
. New research supports theory that indirect transmission of chronic wasting disease11
. Animal studies show promise treating severe chronic pain